epigenetic research

SKLB-03220 是一种口服活性的共价抑制剂，靶向组蛋白甲基转移酶 EZH2，该酶为已知的参与观遗传调控的肿瘤学化合物靶点。SKLB-03220 的结构基于临床批准的 EZH2 抑制剂 tazemetostat，并能够消除表观遗传 H3K27me3 标记，改变染色质状态及转录活性。SKLB-03220 是癌症表观遗传研究中强效的小分子工具化合物。

EPZ-719 is a highly selective and potent inhibitor of SETD2, a novel compound known for its ability to inhibit the enzymatic activity of SETD2 (IC50 = 0.005 μM). This compound displays a remarkable selectivity over other histone methyltransferases, making it a promising candidate for targeted therapeutic applications in the field of epigenetic research.

3-Methylcytidine (methosulfate), a derivative of cytidine, serves as an internal standard for HPLC and is recognized for its epigenetic modification in tRNA, although its cellular role remains unclear. Research has explored its utility as a cancer biomarker, with findings indicating a notable increase in the urine of breast cancer patients.